- Home
- CAL vs BCYC Comparison
CAL vs BCYC Comparison
Compare CAL & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAL
- BCYC
- Stock Information
- Founded
- CAL 1878
- BCYC 2009
- Country
- CAL United States
- BCYC United Kingdom
- Employees
- CAL N/A
- BCYC N/A
- Industry
- CAL Shoe Manufacturing
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- CAL Consumer Discretionary
- BCYC Health Care
- Exchange
- CAL Nasdaq
- BCYC Nasdaq
- Market Cap
- CAL 520.3M
- BCYC 566.5M
- IPO Year
- CAL N/A
- BCYC 2019
- Fundamental
- Price
- CAL $13.46
- BCYC $8.22
- Analyst Decision
- CAL Hold
- BCYC Buy
- Analyst Count
- CAL 1
- BCYC 10
- Target Price
- CAL $14.00
- BCYC $25.00
- AVG Volume (30 Days)
- CAL 1.2M
- BCYC 333.0K
- Earning Date
- CAL 05-29-2025
- BCYC 05-01-2025
- Dividend Yield
- CAL 2.08%
- BCYC N/A
- EPS Growth
- CAL N/A
- BCYC N/A
- EPS
- CAL 2.43
- BCYC N/A
- Revenue
- CAL $2,677,706,000.00
- BCYC $25,722,000.00
- Revenue This Year
- CAL $0.93
- BCYC N/A
- Revenue Next Year
- CAL $3.13
- BCYC $1.83
- P/E Ratio
- CAL $5.54
- BCYC N/A
- Revenue Growth
- CAL N/A
- BCYC N/A
- 52 Week Low
- CAL $13.14
- BCYC $6.10
- 52 Week High
- CAL $44.51
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- CAL 35.14
- BCYC 49.16
- Support Level
- CAL $15.68
- BCYC $8.00
- Resistance Level
- CAL $16.86
- BCYC $8.73
- Average True Range (ATR)
- CAL 0.82
- BCYC 0.48
- MACD
- CAL -0.35
- BCYC 0.02
- Stochastic Oscillator
- CAL 6.24
- BCYC 33.33
About CAL Caleres Inc.
Caleres Inc is a footwear company that operates retail shoe stores and e-commerce websites, and designs, develops, sources, manufactures, and distributes footwear for people of all ages. The Company's business operations are organized into two reportable segments - famous Footwear and Brand Portfolio. The famous Footwear segment is comprised of its famous Footwear retail stores, famousfootwear.com, and famousfootwear.ca. The famous Footwear segment operated around 846 stores at the end of 2024. The Brand Portfolio segment offers retailers and consumers a cultivated portfolio of known brands. Geographically, the company generates the majority of its revenue from Domestic operations.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.